Inspire Medical Systems, Inc. (NYSE:INSP) Shares Sold by Amundi

Amundi reduced its stake in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) by 10.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 203,353 shares of the company's stock after selling 22,479 shares during the period. Amundi owned approximately 0.68% of Inspire Medical Systems worth $37,698,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Farther Finance Advisors LLC raised its position in Inspire Medical Systems by 1,158.3% in the 3rd quarter. Farther Finance Advisors LLC now owns 151 shares of the company's stock valued at $32,000 after purchasing an additional 139 shares in the last quarter. QRG Capital Management Inc. acquired a new stake in Inspire Medical Systems in the third quarter valued at approximately $236,000. Principal Financial Group Inc. lifted its stake in Inspire Medical Systems by 3,812.6% in the third quarter. Principal Financial Group Inc. now owns 141,089 shares of the company's stock worth $29,777,000 after acquiring an additional 137,483 shares during the last quarter. Crossmark Global Holdings Inc. grew its holdings in Inspire Medical Systems by 38.2% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 2,422 shares of the company's stock worth $511,000 after acquiring an additional 670 shares in the last quarter. Finally, Aigen Investment Management LP purchased a new stake in shares of Inspire Medical Systems in the 3rd quarter valued at approximately $649,000. 94.91% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of brokerages recently commented on INSP. Wells Fargo & Company lowered their target price on shares of Inspire Medical Systems from $198.00 to $195.00 and set an "equal weight" rating for the company in a research note on Tuesday, February 11th. Royal Bank of Canada reaffirmed an "outperform" rating and set a $260.00 price objective on shares of Inspire Medical Systems in a research report on Tuesday, February 11th. Bank of America upgraded Inspire Medical Systems from a "neutral" rating to a "buy" rating and increased their price objective for the company from $220.00 to $255.00 in a report on Wednesday, November 20th. Truist Financial decreased their target price on Inspire Medical Systems from $250.00 to $235.00 and set a "buy" rating for the company in a research note on Tuesday, February 11th. Finally, Morgan Stanley dropped their price target on shares of Inspire Medical Systems from $230.00 to $220.00 and set an "overweight" rating on the stock in a research note on Tuesday, February 11th. Three equities research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and a consensus price target of $228.82.

Remove Ads

Insider Buying and Selling at Inspire Medical Systems

In other Inspire Medical Systems news, insider Randy Ban sold 25,584 shares of the company's stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $183.50, for a total transaction of $4,694,664.00. Following the completion of the transaction, the insider now owns 7,259 shares in the company, valued at approximately $1,332,026.50. This represents a 77.90 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CTO John Rondoni sold 583 shares of Inspire Medical Systems stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total transaction of $99,395.67. Following the completion of the sale, the chief technology officer now directly owns 10,424 shares in the company, valued at approximately $1,777,187.76. The trade was a 5.30 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 26,225 shares of company stock valued at $4,806,530 in the last ninety days. Insiders own 4.10% of the company's stock.

Inspire Medical Systems Trading Down 5.7 %

Shares of INSP opened at $163.01 on Thursday. The company's 50 day simple moving average is $186.26 and its 200-day simple moving average is $192.40. Inspire Medical Systems, Inc. has a 12-month low of $123.00 and a 12-month high of $257.40. The firm has a market cap of $4.84 billion, a PE ratio of 94.22, a price-to-earnings-growth ratio of 2.86 and a beta of 1.48.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last posted its quarterly earnings data on Monday, February 10th. The company reported $1.15 EPS for the quarter, beating analysts' consensus estimates of $0.74 by $0.41. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. As a group, equities research analysts forecast that Inspire Medical Systems, Inc. will post 2.16 EPS for the current fiscal year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.

Want to see what other hedge funds are holding INSP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Inspire Medical Systems, Inc. (NYSE:INSP - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.